Murase, and H
Read review Dihexa for Autism Spectrum Disorder (ASD) The Campbell rs1858830 MET promoter C-allele autism finding (the strongest mechanistic anchor to Dihexa pharmacology), the January 2026 mGluR5 PET 16-23% lower availability, the December 2025 DAYBUE STIX (trofinetide) Rett approval, the March 2026 FDA leucovorin decision (CFD only, not autism), the 270,701 NHS open referrals breaching NICE NG142, and the ~700,000 UK autistic population
No, the FDA has not approved Glutathione IV treatment
If the request meets pre-set criteria, the payer can send an immediate auto-approval response
However, both medications carry individual side effect profiles that your prescriber should review together: GLP-1 drugs can cause nausea and gastrointestinal changes, while testosterone may increase blood pressure or hematocrit in some men
Association between Epstein-Barr-Virus reactivation and development of Long-COVID fatigue
